G-CAN 2023 EARLY CAREER INVESTIGATOR ABSTRACT SYMPOSIUM AWARD RECIPIENTS

G-CAN 2023 H. Ralph Schumacher Memorial Early Career Investigator Award

Riku Takei, United States; *Tony Merriman, Mentor* Genetic colocalization of gout with plasma and urine metabolites.

SPARK (Select Presentation of Abstract Research Keynotes) Presenters

- 1. **Orsolya Gaal,** Cluj-Napoca, Romania; *Leo Joosten, Mentor* Interleukin 1 receptor type I and II variation in patients with gout and hyperuricemic individuals.
- 2. **Dansoa Tabi-Amponsah**, Auckland, New Zealand; *Nicola Dalbeth, Mentor*Dual energy computed tomography (DECT) urate volume predicts fulfillment of gout remission after two years of intensive urate-lowering therapy.
- 3. **Tom Niessink,** Enschede, Netherlands; *Cees Otto, Mentor*Automated classification of Raman spectra for an objective diagnosis of crystal arthropathies.
- 4. **Nick Sumpter,** Birmingham, United States; *Tony Merriman, Mentor* Why 6.8?
- 5. **Brenda Kischkel,** Nijmegen, the Netherlands; *Leo Joosten, Mentor*Differences in the inflammatory proteome of gout patients during flare, inter-critical and T2T conditions reveals new biomarkers for the disease.
- 6. **Panagiota Drivelegka,** Gothenburg, Sweden; *Lennart Jacobsson, Mentor* In-hospital treatment, secondary prevention, and mortality after first-ever acute myocardial infarction in patients with gout.
- 7. **Chesca Barrios,** Los Angeles, United States; *John Fitzgerald, Mentor*Using a new engineering method, single-shot computational polarized light microscopy (SCPLM), in identifying crystals in synovial fluid.

MAPS (Mini-Lecture Abstract Presenters Session) PRESENTERS

 Lindsay Helget, United States; Ted Mikuls, Mentor Gout: A Gateway to Chronic Opioid Use?

Allyson Covello, New York, United States; Michael Pillinger, Mentor
 Skeletal Muscle Mass and Quality in Gout Patients Versus Non-Gout Controls: A Computed Tomography Imaging Study.

3. **Vicky Tai,** Dunedin, New Zealand; *Nicola Dalbeth, Mentor*An updated systematic review and meta-analysis of randomized controlled trials on the effects of urate-lowering therapy initiation during a gout flare.

4. **Medeea Badii,** Romania; *Leo Joosten, Mentor*Sex-specific differences in cytokine levels in patients with gout compared to controls.

Elizabeth Lopez, Birmingham, United States; Maria Danila, Mentor
 Socioeconomic disadvantage and Outpatient Follow-Up After an Emergency Department Visit for Acute Gout Flare.

6. **Silvia Sirotti,** Milan, Italy; *Georgios Filippou, Mentor*Could the extent of CPP deposition provide novel insights in the pathogenetic mechanisms of CPPD? Preliminary results of an ultrasound study.

7. **Liu Shuang,** Shanghai, China; *Haibing Chen, Mentor*Clustering of gout-related comorbidities and their relationship with gout flares: a data-driven cluster analysis of eight comorbidities.

8. **Silvia Sirotti** Milan, Italy; *Georgios Filippou, Mentor*Histological characterization of menisci in patients with osteoarthritis and calcium pyrophosphate deposition (CPPD).

9. **Nick Sumpter,** Birmingham, United States; *Tony Merriman, Mentor* Sex ratios in gout.

10. **Dansoa Tabi-Amponsah,** Auckland, New Zealand; *Nicola Dalbeth, Mentor* The Patient Experience of Gout Remission: A Qualitative Study.

11. **Tom Niessink,** Enschede, the Netherlands; *Cees Otto, Mentor*Identification of calcium crystals in pre-operative synovial fluid samples from patients with endstage knee osteoarthritis.

12. Ellen Prendergast, Dunedin, New Zealand; *Lisa Stamp, Mentor*Adherence to the Gout and Crystal Arthritis Network (G-CAN) Consensus Statements for Gout Nomenclature.

13. **Silvia Sirotti,** Milan, Italy; *Georgios Filippou, Mentor*The impact of the 2011 EULAR recommendations for the nomenclature of CPPD in the terminology used in the literature.

14. **Nicole Leung,** New York, United States; *Michael Pillinger, Mentor*Peripheral Arterial Disease and Sequelae in Individuals with Gout, Diabetes, or Both: A US
Veterans Population-based Study.

15. **Gao Yining,** Shanghai, China; *Haibing Chen, Mentor*Evaluation of early-life factors and future gout: a prospective cohort study.